President Donald Trump is expected to announce Monday a possible link between Tylenol use and autism risk, according to The Washington Post — a claim likely to draw strong reaction from the medical community.
The reported warning will be part of what Trump called an “amazing” public health announcement at the White House. Health and Human Services Secretary Robert F. Kennedy Jr., a longtime critic of mainstream medical guidance, is expected to feature prominently in the event.
IN CASE YOU MISSED IT | HHS Secretary Kennedy targets causes of autism, report due next month
“I think it’s going to be one of the most important news conferences I’ll ever have and I look so forward to it,” Trump said Sunday.
Trump discussed the upcoming announcement Sunday during a memorial for conservative activist Charlie Kirk in Arizona and suggested it will include a new treatment option for autism.
“We’re going to be talking in the Oval Office and White House about autism, how it happens, so we won’t let it happen anymore, and how to get at least somewhat better when you have it so that parents can help their child — their beautiful child,” Trump said.
Tylenol’s manufacturer has not yet responded publicly to the reported claim. Medical experts and public health officials have previously cautioned against drawing causal links between over-the-counter medications and autism without substantial peer‑reviewed evidence.
IN RELATED NEWS | RFK Jr. disputes CDC conclusion on why autism rates have jumped in US
Kennedy’s appearance is expected to generate controversy; he has faced weeks of criticism from doctors, scientists and health agencies over past statements on vaccines and other health issues.
Autism Speaks, a nonprofit advocacy group, reports one in 31 children in the U.S. has a form of autism, along with one in 45 adults.
This story was initially reported by a journalist and has been converted to this platform with the assistance of AI. Our editorial team verifies all reporting on all platforms for fairness and accuracy.
